Adjuvant Treatment with Opdivo Demonstrates Statistically Significant and Clinically Meaningful Improvement in Disease-Free Survival in Patients with Muscle-Invasive Urothelial Carcinoma in Phase 3 CheckMate -274 Trial Biotech Investing
OPDIVO® in Combination with CABOMETYX® Shows Sustained Survival and Response Rate Benefits as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma in the Phase 3 CheckMate -9ER Trial Biotech Investing
Bristol Myers Squibb Receives European Commission Approval for Inrebic® for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis Biotech Investing
Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting Medical Device Investing
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi , a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma Biotech Investing
Bristol Myers Squibb to Participate in Guggenheim's Virtual Healthcare Talks | 2021 Oncology Day Biotech Investing
